堃博醫療-B(02216.HK):一次性使用內窺鏡霧化微導管中國獲批上市 開闢藥械結合廣泛應用場景
格隆匯10月31日丨堃博醫療-B(02216.HK)發佈公吿,2022年10月28日,公司藥械結合領域的創新產品“霧泉TM”一次性使用內窺鏡霧化微導管正式獲得浙江省藥品監督管理局批准上市。
根據披露,該產品是截至目前中國唯一獲批的霧化微導管,擁有多項專利技術,適應症廣,可適配多類藥物,開闢肺部疾病治療領域廣泛的藥械結合應用場景。該產品與內窺鏡配合使用,在導航系統引導下,精準抵達病灶,用於灌洗、噴灑藥液或配合造影劑使用。霧化微導管頭端的專利微流道芯片及高壓輸注可將藥物顆粒粒徑縮小至20微米(μm)的霧粒,藥物可與局部病變直接接觸,分佈更均勻,使得局部藥物濃度顯著增高,可直接增強治療效果。導管本體採用安全材質,藥物相容性高,可以適配多種藥物,其前端鈍圓型設計讓醫生操作中推送順滑並保護支氣管管壁,降低組織損傷風險。
公吿表示,公司深耕肺部疾病介入治療器械多年,霧化微導管是其在藥械結合領域的首項成果,未來公司將與臨牀專家及生物製藥企業聯合,探索霧化微導管應用於支氣管鏡手術麻醉、結核病治療、腫瘤藥物靶向給藥等,並持續拓展其使用場景,覆蓋更廣範圍的肺部疾病治療,夯實公司在肺部疾病精準介入診療領域的領先優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.